论文部分内容阅读
有关充血性心力衰竭方面的临床和基础研究是积极而富有成果的。但对这类日趋衰弱、身患致命疾病的患者而言。公认的有效治疗药物仅限于三种:洋地黄、利尿剂和血管扩张剂。其中后者已被证实可提高充血性心力衰竭病人的生存率。虽然心脏移植可以使心脏机能明显改善并使有症状的心力衰竭病人的死亡率明显减低,但其代价是昂贵的。选择病人受到限制,并且病人要承担长期使用免疫抑制剂治疗的许多风险。
The clinical and basic research on congestive heart failure is positive and fruitful. But for those who are getting weaker and have a fatal disease. Recognized as effective treatment is limited to three kinds: digitalis, diuretics and vasodilators. The latter has been shown to improve survival in patients with congestive heart failure. Although heart transplantation can significantly improve heart function and significantly reduce the mortality of symptomatic patients with heart failure, the cost is high. The patient choice is limited and the patient has many risks of long-term immunosuppressive therapy.